DOI : 10.1055/s-00000041

Neuropediatrics

Issue S 1 · Volume 37 · 2006 DOI: 10.1055/s-002-4877


10th International Child Neurology Congress (ICNC)
Montreal, Canada, 11–16, June 2006

Chairman: Michael Shevell, Montreal, Canada
Abstracts (HTML) List of Authors
TP68
Tanaka, S.; Araki, A.; Kaneko, K.: SUCCESSFUL MANAGEMENT OF SEIZURES BY PROPHYLACTIC MIDAZOLAM DURING A CONCOMITANT ADMINISTRATION OF CARBAPENEM AND VALPROATE
TP69
Emslie, G. J.; Bangs, M. E.; Spencer, T.; Ramsey, J. L.; Detke, H. C.; Rogers, A. K.; Allen, A. J.; Sumner, C.: ATOMOXETINE IN ADOLESCENTS WITH ADHD AND COMORBID DEPRESSION
TP70
Berger, I.; Daana, M.; Tanenbaum, A.; Taustein, I.; Nevo, Y.: LAMOTRIGINE OVERDOSE IN A CHILD
TP71
Yeh, G. C.; Chen, J. Y. R.: LONG-TERM INCUBATION OF LOW CONCENTRATION OF ARACHIDONIC ACID PROMOTES THE DIFFERENTIATION OF PC-12 CELLS TOWARD CHOLINERGIC-LIKE NEURON IN THE PRESENCE OF NGF
TP72
Wilens, T. E.; Newcorn, J. H.; Kratochvil, C.; Gao, H.; Thomason, C.; Rogers, A. K.; Feldman, P.; Levine, L. R.: EFFECTS OF LONGER-TERM ATOMOXETINE TREATMENT IN ADOLESCENTS WITH ADHD
TP73
Kelsey, D.; Sutton, V.; Schuh, K.; Trzepacz, P.; Sumner, C.: ONCE-DAILY ATOMOXETINE FOR ADHD: UPDATE ON EVENING AND MORNING BEHAVIOR
TP74
Sumner, C.; Sher, L.; Sutton, V.; Bakken, R.; Paczkowski, M.; Trzepacz, P.; Kelsey, D.: ATOMOXETINE TREATMENT FOR PEDIATRIC PATIENTS WITH ADHD AND COMORBID ANXIETY
TP75
Kratochvil, C.; Wilens, T.; Greenhill, L.; Gao, H.; Thomason, C.; Dickson, R.; Gelowitz, D.: LONG-TERM ATOMOXETINE ADMINISTRATION FOR YOUNG CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
TP76
Allen, A. J.; Bymaster, F.; Michelson, D.; Thomason, C.; Kallman, M.; Jasinski, D.; Dickson, R.; Clarke, D.: A REVIEW OF THE ABUSE LIABILITY OF ATOMOXETINE, A NONSTIMULANT PHARMACOTHERAPY FOR ADHD
TP77
Tenembaum, S.; Segura, M.: INTERFERON BETA-1A TREATMENT IN EARLY-CHILDHOOD AND JUVENILE MULTIPLE SCLEROSIS
TP78
Soman, T.; Hune, S.; Rafay, M.; Allen, A.; MacGregor, D.; Chan, A.; deVeber, G.: USE OF CLOPIDOGREL IN PEDIATRIC ARTERIAL ISCHEMIC STROKE: SAFETY AND ADVERSE EFFECTS